"Proteasome Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the function or proteolytic action of the PROTEASOME.
- Proteasome Inhibitors
- Inhibitors, Proteasome
- Proteasome Inhibitor
- Inhibitor, Proteasome
- Proteasome Endopeptidase Complex Inhibitors
Below are MeSH descriptors whose meaning is more general than "Proteasome Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proteasome Inhibitors".
This graph shows the total number of publications written about "Proteasome Inhibitors" by people in this website by year, and whether "Proteasome Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Proteasome Inhibitors" by people in Profiles.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274.
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proc Natl Acad Sci U S A. 2021 04 27; 118(17).
In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. Aging (Albany NY). 2020 11 16; 12(22):22949-22974.
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.
FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 08 09; 3(15).
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876.
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017 11; 31(11):2443-2448.